索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • 期刊摘要索引目录
  • OCLC-WorldCat
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Should a More Personalized Approach be Applied to Hematopoietic Stem-Cell Transplantation?

Stefan O Ciurea, Piyanuch Kongtim, Gabriela Rondon, Julianne Chen, Ciprian Tomuleasa and Richard E Champlin

Background: Allogeneic stem cell transplantation for older patients with hematological malignancies has generally been performed with reduced-intensity conditioning, as regimen-related toxicity prohibits a fully myeloablative conditioning regimen. We hypothesized that differences in intensity of conditioning are needed for different disease status.
Patients and Methods: We analyzed 115 older patients with AML (55 years or older) who received conditioning with fludarabine and melphalan, with a melphalan dose of 140 mg/m2 (FM140) (N=73) or 100 mg/m2 (FM100) (N=42).
Results: Overall, FM100 was associated with less TRM (18.1% versus 43.5%, p=0.007), and acute GVHD (aGVHD) (28.2% versus 36.7%, p=0.021) while relapse was similar (21.5% versus 25.5%, p=0.489). The lower TRM with comparable relapse rate resulted in higher survival for FM100 as compared with FM140 conditioning regimen, 3-year PFS was 60.2% and 28.6% (p=0.014). Conversely, patients with high-risk SWOG cytogenetics and adverse ELN risk had better survival outcomes with FM140 regimen due to lower relapse, while TRM was not different. In multivariable analysis, high-risk SWOG cytogenetics, adverse ELN risk and the development of grade 2-4 aGVHD predicted for worse PFS whereas using FM140 conditioning and aGVHD were an independent factor for TRM.
Conclusion: These results suggest as a proof-of-principle that a differential approach should be applied for patients receiving an allogeneic hematopoietic stem cell transplant, not only based on age, but also on disease characteristics impacting the risk of relapse. Further studies are needed to develop a more personalized approach to hematopoietic stem cell transplant recipients.